Vaccine uptake and barriers to vaccination among at-risk adult populations in the US
Irina Kolobova\textsuperscript{a}, Mawuli Kwame Nyaku\textsuperscript{a}, Anna Karakusevic\textsuperscript{b}, Daisy Bridge\textsuperscript{b}, Iain Fotheringham\textsuperscript{b}, and Megan O’Brien\textsuperscript{b}

\textsuperscript{a}Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA; \textsuperscript{b}Adelphi VALUES PROVE, Cheshire, UK

ABSTRACT
To reduce morbidity and mortality associated with vaccine-preventable diseases (VPD), it is imperative that vaccination programs are implemented and prioritized throughout all stages of life across all populations. This study aimed to determine vaccine uptake and barriers to vaccination among VPDs at-risk adult populations in the United States. We conducted a systematic literature review for articles published between January 2010 and June 2020 and identified 153 publications. The review identified 17 at-risk populations. Vaccine uptake was suboptimal among many populations, with factors including age, gender, and disease severity, associated with uptake. This review identified several barriers that impact vaccine uptake among at-risk populations, with concerns over safety, vaccine costs, lack of insurance, and lack of provider recommendation commonly reported across populations. Embracing a national life-course immunization framework that integrates developing policies, guidelines, and education would be a step to addressing these barriers.

Introduction
Vaccines are critical to the prevention and control of vaccine-preventable diseases (VPDs) and therefore underpin global health security.\textsuperscript{1} Vaccination throughout life brings significant benefits at the individual, community, and socio-economic levels.\textsuperscript{2-4} Despite the contribution of vaccination in reducing the burden of VPDs, these diseases continue to confer a significant burden on society and the healthcare system.\textsuperscript{5} Furthermore, not all individuals experience the same risk of VPDs, and those defined as at-risk populations in the Advisory Committee on Immunization Practices (ACIP) recommendations due to existing health conditions, occupational risks, or behavior are classified at increased risk.\textsuperscript{3, 4, 6-7} This is especially relevant because herd immunity is not sufficient to prevent or reduce the substantial morbidity and mortality among these populations.\textsuperscript{2, 7, 8} This is of particular importance given the risk of worse clinical outcomes, including more frequent hospitalizations and increased length of stay, experienced among at-risk groups compared to the general population.\textsuperscript{2, 7, 8}

To reduce morbidity and mortality associated with VPDs, it is imperative that vaccination programs are implemented and prioritized across all populations.\textsuperscript{3-5} The concept of a life-course approach to immunization is to protect individuals against VPDs and provide health benefits including reducing hospitalizations and healthcare costs to individuals throughout their lives, at different ages and situations, including at-risk populations.\textsuperscript{2} The World Health Organization (WHO) Immunization Agenda 2030 established life-course immunization as a strategic priority, with mobilizing support among at-risk groups as one of the key areas of focus.\textsuperscript{1} The life-course immunization framework involves comprehensive immunization programs, with clear guidelines, vaccine access, data generation, and community partnerships.\textsuperscript{2} Furthermore, these programs involve public demand for vaccination, engaged healthcare workers (HCWs), and robust surveillance and vaccine uptake data informing policies and programs.\textsuperscript{1, 2} Understanding vaccine uptake and the impact of VPDs among at-risk populations is critical for informing a life-course immunization framework for immunization.\textsuperscript{2, 7, 8}

Despite the widespread and marked impact VPDs have on individual health, the healthcare system and on the economy, to the authors’ knowledge, no review has thoroughly explored vaccine uptake and barriers to vaccination among at-risk populations in the United States (US). This knowledge is imperative to understand the benefits of a life-course approach to immunization among individuals in this group.

In order to support disease prevention among at-risk adults, similar to the achievement of successful vaccine recommendations and immunization frameworks among pediatric and older adult populations, this systematic literature review (SLR) sought to identify evidence related to VPDs among at-risk adult populations. The objectives of the overall SLR were therefore to (1) quantify the epidemiological burden of VPDs among the at-risk populations of interest; (2) determine the clinical, economic, and societal burden of VPDs among these populations; and (3) determine current vaccine uptake and barriers to vaccination. This review identified a substantial volume of data on disease burden and vaccine uptake and therefore focuses on determining current vaccine uptake and barriers to vaccination (objective 3). A companion article will explore the first and second objectives on quantifying the burden of VPD.
Methods

Search strategy
We searched Medline, Embase, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials for articles published between January 2010 and June 2020. The search comprised combinations of keywords and Medical Subject Headings (MeSH) terms pertaining to at-risk populations, VPDs, epidemiology, clinical, economic, and societal burden, and vaccine uptake (Table S1). We reviewed bibliographies of included publications to identify relevant publications not captured through the database searches. We performed a gray literature search of the Centers for Disease Control and Prevention (CDC), Office of Disease Prevention and Health Promotion, US Department of Health & Human Services, and Immunization Action Coalition websites.

Study selection
We reviewed all identified references for inclusion at the title and abstract level. Full-text screening was conducted by two reviewers using the population, comparators, outcomes, and study design (PICOS) framework (Table S2). Briefly, included articles were primary studies that met the following criteria: (1) individuals defined as at-risk by the ACIP recommendations and CDC adult immunization schedule; (2) epidemiology, economic, and social burden outcomes; (3) vaccination outcomes; (4) studies conducted with US adults (≥19 years). Following a double-blind review, all discrepancies identified were resolved by consensus with a senior researcher.

Data were extracted on the epidemiology, economic, social burden, and vaccination outcomes into a data extraction form by one reviewer and checked for accuracy by a second reviewer.

Results

Overview of results
The search, ran on July 31st, 2020, identified 6,076 articles from both database and gray literature searches, of which 458 were taken forward to full-text review. After screening against the eligibility criteria, 196 publications were included (Figure 1). As this paper aims to evaluate vaccine uptake and barriers to vaccination of VPDs among at-risk populations, only studies reporting these outcomes were included (N = 153).

The SLR identified publications reporting vaccination uptake for 17 at-risk populations. The greatest number of publications were identified among pregnant women (N = 53) and individuals with occupational exposures (N = 31), followed by men who have sex with men (MSM; N = 19). The following sections present trends among populations where ≥5 publications reported on vaccine uptake or barriers to vaccination.

Vaccine uptake and barriers to vaccination
Vaccine uptake among at-risk populations was reported in 150 studies, with over a third reporting on pregnant women (N = 53). Barriers to vaccination among at-risk populations were reported in 107 studies; the greatest number reported on pregnant women (N = 46). There was variation in available data, with limited (<5 publications) or no data available for 13 at-risk populations (Table S2). Frequently reported barriers to vaccination included concerns regarding vaccine safety or efficacy, vaccine hesitancy, lack of insurance, cost of vaccination, perceived lack of risk, and lack of guidelines or education and HCW recommendation. The entire dataset for all populations is reported in Tables S4 and S5 in the appendices.

Occupational exposures

Vaccine uptake. Thirty-three publications reported vaccine uptake in individuals with occupational exposures and notably, HCWs were the only population identified. There was large heterogeneity in the data, with 18 studies reporting influenza vaccine uptake; estimates ranged between 32.0% and 91.6% for overall vaccine uptake among HCWs.9–23 Notably, the annual survey of HCW influenza vaccine uptake conducted by the CDC highlighted that uptake has been steadily increasing over the past 10 years (Figure 2).24–30 Uptake was highest among HCWs working in hospitals and lowest among HCWs in long-term care settings.19 Furthermore, HCWs with health conditions, such as asthma, diabetes, or human immunodeficiency (HIV) infection, were more likely to be vaccinated than healthy controls.23

Several studies evaluated the impact of mandated vaccination among HCWs for influenza and Tdap vaccines.10,12,14,31,32 A study of HCWs in a long-term acute care facility reported that the implementation of mandated influenza vaccination increased vaccination rates from 25% (N = 272) in 2008–2009 to 65% (N = 279) in the 2010–2011 influenza season (p < .05).12 A further study of HCWs during a pertussis epidemic reported that mandated Tdap vaccination improved vaccination rates from 67% to 92%.32 However, opposition to vaccine mandates was reported with HCWs stating that mandates are an infringement on workers’ rights and, in some instances, HCWs reported that they would seek employment elsewhere.32

Among the three studies reporting on tetanus, diphtheria, and pertussis (Tdap) vaccine, uptake estimates among HCWs ranged between 39.0% and 97.0%.31–33 Notably, a study of HCWs in California reported that Tdap uptake improved with increased influenza vaccination (2008–2009: 60%; 2009–2010: 63%).31,32

A study of Native Hawaiian and Pacific Islanders reported a hepatitis B virus (HBV) vaccine uptake of 65.6% among HCWs.34 Furthermore, HBV vaccination for HCWs was 4.8 (95% CI; OR 1.7–14.0) times higher than for non-providers.34 A second study reported suboptimal hepatitis A virus (HAV) vaccine uptake among HCWs in Texas (28.9%; N = 60/207), with only half receiving the full vaccination series.35

Barriers to vaccination. Cost and perceived safety of vaccination were identified as barriers to vaccination among HCWs. Among HCWs who did not receive the pertussis vaccination (61%), 55% (N = 83) cited concerns about the safety of the vaccine, while 14% cited their physicians not recommending it, and 14% cited lack of awareness of current guidelines.32
Figure 1. PRISMA diagram.

Figure 2. Influenza vaccine uptake among HCWs, by year.22–28
Furthermore, there is evidence indicating that, when cost is removed as a barrier, vaccine uptake among HCWs increases. Vaccine uptake among HCWs who worked in locations where their employer made vaccination available on-site at no cost for >1 day was 83.9%. Uptake was 59.5% among HCWs who worked in locations where their employer did not freely provide influenza vaccination on-site, but actively promoted vaccination through other mechanisms.

**Tourists/travelers**

**Vaccine uptake.** Ten publications reported on vaccine uptake among tourists and travelers. Uptake rates among tourists/travelers differed by vaccine, with estimates ranging from 36.0% to 67.0% for influenza, 25.9% to 40.2% for HBV, 18.8% to 48.3% for HAV and 23.0% to 72.0% for MMR. Notably, age, receipt of influenza vaccine, education, and health insurance, among others, were all independently associated with vaccine uptake with regional variations noted.

**Barriers to vaccination.** Limited awareness about the specific vaccines recommended for different global regions, provider decisions, lack of insurance and the costs of vaccination were identified as barriers to vaccination among tourists/travelers (Table S4). For example, in a 2017 study among travelers eligible for MMR, 48% (N = 1,689) travelers refused the vaccine either due to not being concerned about illness, or cost concerns. Furthermore, 28% of travelers (N = 966) did not receive the vaccine due to provider decisions.

**Migrants/immigrants**

**Vaccine uptake.** Among the eight studies reporting on vaccine uptake among migrants/immigrants, suboptimal HBV uptake was identified (compared to the Healthy people 2020 goal of 60%), with estimates ranging between 8.4% and 54.7%. Comparing vaccination between US- and foreign-born women of reproductive age, using NHIS data, lower HBV uptake was identified among foreign-born women (27.3% versus 40.9%).

Initiation of human papillomavirus (HPV) vaccination was also found to be low among immigrants where a 2019 study reported only 6.7% (N = 22) of foreign-born US patients had initiated a vaccination series.

Vaccine uptake also varied depending on country of birth. A 2014 study compared influenza and pneumococcal uptake between European-born, Arab-born and US-born individuals using NHIS data (N = 117,893). Vaccine uptake was lower among European- and Arab-born individuals than US-born individuals for both pneumococcal (84% and 89% not vaccinated versus 78%, respectively) and influenza vaccination (71% and 74% not vaccinated versus 64%, respectively).

**Barriers to vaccination.** Access to healthcare and educational attainment level were identified as key barriers to vaccination among Latino and Asian migrants and immigrants. A study of US- and foreign-born women reported that fewer foreign-born women were insured than US-born women (68.2% versus 86.4%, respectively) and fewer foreign-born women had visited a healthcare provider in the past year (74.4% versus 85.3%, respectively). Similarly, a 2013 study of Laotian immigrants in Minnesota identified limited English fluency (12%) and not knowing where to go for vaccination (22.6%) as important barriers to vaccination.

**Liver disease**

**Vaccine uptake.** Six studies reported on vaccine uptake among patients with chronic liver disease (CLD). Uptake of HAV and HBV vaccination ranged from 6.7–40.5% and 8.2–53.8%, respectively, with rates increasing in recent years (Figure 3). Over the same period, the number of individuals receiving <2 recommended doses decreased from 46.7% to 9.3% for HAV, and from 17.9% to 7.0% for HBV.

A 2012 survey study utilizing data from the 2007 to 2011 National Health and Wellness Survey reported uptake rates of 34.9% for HAV and 40.5% for HBV vaccination, both of which were found to be significantly greater among patients with CLD when compared with healthy individuals (p < .05).
However, uptake has been found to vary with age. A 2016 study of 32,296 individuals using NHIS data reported higher uptake among patients with CLD aged 19–49 compared with those aged ≥50 years for both HAV (18.2% versus 12.3%) and HBV (41.6% versus 25.1%).

**Barriers to vaccination.** No publications reported on the barriers to vaccination among individuals with CLD.

### People with diabetes

**Vaccine uptake.** Among the nine studies reporting on vaccine uptake among people with diabetes, uptake estimates ranged from 37.0% to 53.0% for pneumococcal, 9.4% to 30.7% for HAV and 13.5% to 39.0% for HBV, and 41.0% to 79.5% for influenza. Notably, vaccine uptake was consistently lower among people with diabetes compared with the general population (15.4% versus 20.5% for HAV; 22.4% versus 34.3% for HBV in 2008). A 2016 national survey of 32,296 individuals reported low HBV vaccine uptake among people with diabetes, with age negatively associated with vaccination (23.5% among those aged 19–59 years versus 13.5% for those ≥60 years). Comparatively, a 2016 retrospective cohort study of 245,480 individuals reported that age was positively associated with influenza vaccination, with uptake increasing from 45.8% among those aged 18–49 to 56.6% among those aged 50–65 years with diabetes.

**Barriers to vaccination.** No publications reported on the barriers to vaccination among people with diabetes.

### End-stage renal disease

Among the ten studies reporting on vaccine uptake among patients with end-stage renal disease (ESRD), uptake estimates ranged from 18.7% to 68.7% for influenza, 39.0% to 59.7% for pneumococcal, and 21.6% to 80.1% for HBV. Within these estimates, variation was noted according to disease severity, the presence of a comorbidity and according to race.

**Barriers to vaccination.** No publications reported on the barriers to vaccination among patients with ESRD.

### People living with HIV

Fourteen publications reported vaccine uptake among people living with HIV (PLWH), among a range of vaccines, including HBV, meningococcal disease, influenza, pneumococcal disease, and HPV. Uptake of HBV vaccination ranged from 28% to 45%. HBV uptake differed based on the location where patients received HIV care. A significantly larger percentage of patients who received care at Ryan White HIV/AIDS Program (RWHAP)-funded facilities versus non-RWHAP-funded facilities were vaccinated (12.5% versus 3.7%; p < .001). Conversely, fewer patients who received care at private practices (versus non-private) were vaccinated (5.6% versus 11.8%; p < .001). In a 2011 study reporting influenza uptake using data from the HIV outpatient study (N = 5,365), annual uptake ranged from 25.8% to 43.3%. Influenza uptake in this study was highest among individuals aged 30–39 years (40.0%) and lowest in those aged ≥50 years (14.2%).

Two studies reported similar rates of pneumococcal vaccination: 13.1% among PLWH in Texas and 13.8% among PLWH in California. A third study reported that individuals aged ≥65 years had the highest uptake (59.7%) and those aged 18–49 years had the lowest (16.7%).

**Barriers.** Concerns about the effectiveness of vaccination and lack of insurance or provider recommendation were identified as barriers to vaccination among PLWH. A 2010 cohort study of 1,293 women living with HIV cited beliefs about the effectiveness of influenza vaccination as an important barrier to uptake. Within this study, those who were vaccinated were less likely to report that they were "not at risk of influenza", "flu is not a serious disease" and that "the flu shot made [them] sick".

Further, lack of health insurance and the cost of vaccination have also been cited as prohibitors to vaccine uptake among PLWH. A 2018 cross-sectional study of 18,089 individuals reported that lack of access to affordable vaccines for some PLWH contributed to low vaccine uptake. A 2018 cross-sectional study (N = 18,089) reported that lack of clinical recommendation was an important barrier to vaccine uptake. Similarly, inconsistency among guideline recommendations and reports of reduced immunogenicity among patients with HIV prevented physicians from regularly offering routine vaccination to this group.

### Immunocompromised individuals

Among the 23 publications reporting on vaccine uptake among immunocompromised individuals, uptake estimates ranged from 27.1% to 63.7% for influenza, 7.6% to 59.7% for pneumococcal disease and 19.5% to 33.2% for Tdap. While vaccination rates among those with immunocompromising conditions have increased over time, uptake remains suboptimal against the 2020 Healthy People Goal (60%). A 2018 retrospective study of 35,696,718 individuals reported an increase in pneumococcal vaccine uptake from approximately 20% between 2012 and 2014, to 24% in 2016. Similarly, a 2020 observational study of 91,520 individuals reported increased influenza vaccine uptake among those with reduced kidney function, from 53.3% to 63.7% between 2005 and 2015. Notably, uptake was negatively associated with disease severity, with higher uptake observed among those with normal range kidney function (eGFR ≥60: 62.9% versus eGFR <30: 57.3%).

Similarly, a 2015 retrospective cohort of kidney transplant candidates (N = 363) in Philadelphia reported receipt of other vaccines (OR: 10.55) and dialysis (OR: 2.00) to be significantly associated with increased vaccine uptake (p < .05). However, within this study, both Black (OR: 0.27; <0.001) and Hispanic ethnicity (OR: 0.35; p < .05) were significantly associated with a reduced likelihood of pneumococcal vaccination.
Barriers to recommendation. Missed opportunities for vaccination due to ongoing medical treatments were identified as barriers to vaccination. A 2016 review reporting on vaccination of special populations, including immunocompromised individuals, identified that patients with chronic medical problems may miss routine vaccinations because of frequent hospital admissions. Furthermore, these patients are likely to receive care from a specialist physician rather than a primary care provider; therefore, vaccinations may be missed if specialists assume that vaccination is the responsibility of a general practitioner.57

Injection drug users

Five studies reported on vaccine uptake among injection drug users (IDUs), of which four reported HBV vaccination rates, with estimates ranging from 21.6% to 45.0%. Among MSM in New Orleans, 78 2016 national cross-sectional study reported that at-risk adults tested for HIV at a drug treatment facility were more likely to be vaccinated (OR: 1.73) than IDUs not being tested.77 A fifth study reported lower uptake of the HPV vaccine (15.3%) among females in New Orleans, 78

Barriers to vaccination. No publications reported on the barriers to vaccination among IDUs.

Men who have sex with men

Seventeen studies reported vaccine uptake for HBV, HPV, and meningococcal vaccines among MSM. Among these, HBV vaccine uptake estimates ranged from 14.0% to 50.5%. Conversely, HPV vaccine uptake ranged from 13.0% to 39.8% among individuals completing all three doses of the vaccination series in two separate 2015 national studies.90,91 However, a 2019 study of MSM in Philadelphia reported that only 7.0% of the study population (N = 5,329) received all three vaccine doses.92 Furthermore, a 2016 study (N = 336) reported that HIV-positive MSM were more than twice as likely to be vaccinated compared to HIV-negative men.93

A 2016 study evaluating both HPV and HBV vaccine uptake among MSM in New Orleans (N = 358) reported higher HBV uptake compared to HPV among males (28% versus 14.9%).78 Among MSM, HBV vaccine uptake was associated with having been tested for a sexually transmitted disease (STD) in the past 12 months (p = .019) and having ever received a hepatitis vaccine (p = .004).78 Other sociodemographic factors, such as education, sexual identity and having health insurance, were not significantly associated with HPV vaccine uptake, and only 22.9% of individuals received both HPV and HBV vaccines.

Meningococcal vaccine uptake estimates ranged from 17.0% to 51.3%.94-96 A 2018 cross-sectional survey in California reported that vaccine uptake was higher among HIV-positive versus HIV-negative MSM overall, and in the previous 6 months (82.6% versus 51.3% in the previous 6 months).96

Barriers to vaccination. Lack of insurance, education and provider recommendation were identified as barriers to vaccination. A 2012 nationwide survey reported that individuals who reported being unable to see a doctor because of cost were less likely to be vaccinated against HBV (OR: 0.77, 95% CI: 0.60–0.98).77 Data collected through the National Health and Nutrition Examination Survey (NHANES) survey also identified lack of insurance as a significant negative predictor for vaccination (p < .001).66

In a 2016 study (N = 336), provider recommendation predicted vaccine uptake; individuals who received a recommendation for HPV vaccine were >40 times more likely to have been vaccinated than those without.93

A lack of education regarding HPV vaccination may be a driver of low vaccine uptake among MSM.93,97 A 2013 study reported limited awareness as a reason for being unvaccinated: not knowing that males are allowed to get the HPV vaccination (17%), not having heard of the HPV vaccine (12%) and not knowing enough about the HPV vaccine yet (11%).91

Importantly, many MSM did not disclose their sexuality to their insurance provider or at medical consultations, with one study reporting that 29% (N = 28) of unvaccinated MSM who were not planning on being vaccinated stated that their provider did not know their sexual identity.95 Furthermore, 41% (N = 29) of men who were undecided about receiving vaccination stated that their provider was not aware of their sexuality, indicating an important proportion of at-risk individuals who are therefore not targeted for vaccination recommendation.

Pregnant women

Fifty-three studies reported on vaccine uptake among pregnant women, including influenza vaccination (N = 31), Tdap vaccination (N = 12) and both influenza and Tdap (N = 8). Influenza vaccine uptake ranged from 35.6% to 75.0%,13,40,98-108 The highest overall uptake (75.0%) was reported in a 2018 study of expectant parents in Texas (N = 638).98 Conversely, the lowest (35.6%) was reported in a 2017 nationwide study of pregnant women (N = 2,254).99 Notably, vaccine uptake differed between self-reported and medical record reported uptake, with one study highlighting a clear disparity between the two (self-reported: 71% versus medical record uptake: 36.1%).13

Studies investigating uptake over time typically reported that vaccine uptake has typically increased in recent years (Figure 4 and 5).23,58,109-112 However, a 2016 study of pregnant women in Georgia (N = 8,300) reported that the proportion of women not receiving influenza vaccination had increased from 11.1% in 2004 to 35.8% in 2011.113 The annual CDC reports on influenza and Tdap vaccine uptake consistently identified that older pregnant women had higher rates of influenza vaccine uptake compared to younger women.99-102,111

Overall, Tdap uptake ranged from 14.3% to 58.2%.40,114-121 Similarly to influenza, Tdap uptake among pregnant women has increased in recent years, with a 2017 study (N = 5,606) reporting an increase from <1% (2006–2009) to 54% in 2015.109

Among the eight identified studies reporting on both influenza and Tdap vaccine uptake, Tdap uptake was typically higher than influenza uptake among pregnant women (Tdap: 44.0% to 65.0%; influenza 34.0% to 63.0%).17,102,122-124

Of two studies reporting on hepatitis vaccine uptake in pregnant women, 40 2013 study reported HAV vaccine uptake to be 29.2% among pregnant women in Boston.40 A 2018 study evaluating the difference in HBV vaccine uptake reported this to be higher among US-born versus foreign-born women (45.1% versus 27.6%).45
Barriers to vaccination. Concerns of vaccine safety and effectiveness and lack of provider recommendation and education/guidelines were identified as vaccination barriers. A yearly nationwide survey of influenza vaccination among pregnant women reported that concerns about becoming ill from the vaccine ranged from 10.4% to 21.3% between 2011–2017. Notably, results from the Pregnancy Risk Assessment Monitoring System (PRAMS) survey highlighted that women who had low perceptions of influenza vaccine safety were significantly less likely to intend to receive an influenza vaccine (48% vs. 20%; \( p < .001 \)) or a Tdap vaccine (53% vs. 33%; \( p < .001 \)) during their current pregnancy compared to women who perceived the vaccine as safe. Furthermore, a 2020 survey identified that first-time pregnant women were also more likely to be uncertain about maternal vaccines compared to women with prior children (8% vs. 19%, \( p < .01 \)).

Concerns over the safety of the vaccine for both the mother and their baby was a commonly cited barrier against vaccination. During a study of the 2009–2010 vaccine season by the CDC, among those who did not get vaccinated for influenza (\( N = 2,994 \)), 45.2% women cited they were worried about side effects for themselves and 47.7% were worried the vaccine would harm the baby. Similarly, of those who did not get the H1N1 vaccination, the majority were worried the vaccine would harm themselves (61.4%) or their baby (63.6%).

Lack of provider recommendation was particularly evident among pregnant women, with a 2010 CDC study using PRAMS data reporting that 31.4%/24.8% of pregnant women did not receive the seasonal influenza vaccination/H1N1 vaccination, respectively, because their physician did not recommend it. In a 2012 study investigating PH1N1 vaccine uptake among women during pregnancy (\( N = 4,205 \)), 9.6% of individuals were not vaccinated due to a lack of recommendation from their provider. Conversely, influenza vaccine uptake among pregnant women was highest among women who reported their doctor or other medical professional recommended and offered the vaccination compared to a recommendation but no offer and no recommendation or offer at all. A medical provider’s recommendation also increased the likelihood of accepting the vaccine by 2.6 (\( p < .01 \)).
In a 2018 nationwide internet survey ($N = 2,236$), the most common reason for not receiving Tdap during pregnancy was a lack of knowledge about the need to be vaccinated during every pregnancy (45.1%); 31.6% of women who did not receive vaccine during pregnancy reported having been vaccinated previously, and 13.5% reported not knowing they were supposed to receive Tdap during their recent pregnancy.\textsuperscript{125}

**Discussion**

This review identified that, overall, vaccine uptake has increased across at-risk populations over the past 10 years. Despite this, uptake among at-risk adults was typically below the Healthy People 2020 goal of 60% uptake.\textsuperscript{135} Several barriers to vaccination were commonly reported across populations; including, structural barriers such as cost of vaccination and lack of health insurance, and patient-centered barriers such as concerns regarding vaccine safety and lack of provider recommendation. However, there were limited data reporting on barriers to vaccination among several at-risk populations, including individuals with CLD, ESRD, and IDUs.

Studies have demonstrated that a lack of health insurance coverage and high costs can be an obstacle to vaccination, resulting in a high burden of VPDs among at-risk populations.\textsuperscript{68,72,77} There is evidence that vaccine uptake increases when cost is removed as a barrier; therefore, it is important that there is support from State or Federal policymakers to remove these financial barriers.\textsuperscript{15,136,137} The Affordable Care Act (ACA) mandates that ACIP-recommended vaccines are covered by private insurance plans without a copay, therefore reducing the financial barrier to insured at-risk adults receiving vaccines.\textsuperscript{138} However, the ACA does not require State Medicaid agencies to cover all ACIP recommended vaccines for individuals on Medicaid, resulting in a disparity of coverage compared to individuals with private insurance.\textsuperscript{138} This implies that the cost of vaccination may not be the main barrier to vaccination; however, vaccination cost barriers need to be considered in the context of the potential lack of private insurance among at-risk individuals and a reliance on Medicaid coverage.\textsuperscript{15,126–138}

In order to support effective life-course immunization, it is imperative that HCWs are equipped with the guidelines, training, and tools to provide individualized, patient-centered care. This includes open discussions with patients about the availability of vaccination and the eligibility to receive vaccination.\textsuperscript{139} Additionally, these data emphasize the importance of educating individuals about their increased risk of VPDs and publicly promoting the availability of vaccines to contribute in mitigating this risk.\textsuperscript{139} Integrating vaccination with other primary health care systems, health registers, and notification systems will minimize missed vaccination encounters.\textsuperscript{1} Moreover, telephone and digital reminders to vaccine-eligible adults have proven effective in reducing missed opportunities for vaccination, whilst also benefiting pediatric vaccine coverage.\textsuperscript{1,140}

An important element of life-course immunization is continued education of the public and HCWs to highlight the risk of VPDs and emphasize the important role of vaccination.\textsuperscript{2} In order to overcome barriers related to vaccine safety and effectiveness, wider vaccine education needs to be implemented throughout an individual’s lifetime to reduce vaccine complacency.\textsuperscript{2,7} The wider literature supports the need for more vaccine education materials, outlining facts about vaccines and the diseases they prevent, common misconceptions, and the risks of not getting vaccinated, as key education topics for individuals.\textsuperscript{2–7,135} Studies have indicated that sessions delivering educational interventions greatly increased vaccine knowledge among target groups, such as HCWs, resulting in increased support for vaccination.\textsuperscript{141} This review has identified the need for clear and consistent guidelines for HCWs, since HCW attitude toward vaccination has been recognized as one of the strongest influences on the decision-making of patients.\textsuperscript{7} This is particularly important since there were mixed perceptions and a lack of knowledge around vaccination among HCWs, with some citing safety concerns as a reason for not recommending vaccines for pregnant women.\textsuperscript{13}

Life-course immunization policies, such as the WHO Immunization Agenda 2030, focusing on increasing awareness regarding the health benefits of vaccination, together with cross-sector collaboration to prioritize vaccination, will improve vaccine uptake and reduce the burden of VPDs.\textsuperscript{1,2,4,142} Focused polices and integrated vaccination in public and private payer access programs will promote increased uptake of adult vaccination. It is critical that key stakeholders, including HCWs, are engaged with vaccination policies and guidelines to ensure successful uptake of life-course immunization and reduce missed opportunities for vaccination.\textsuperscript{1,2,4,142}

**Strengths and limitations**

This comprehensive review applied a wide timeframe to ensure all key publications and any key updates in this research area were captured, such as updates to ACIP recommendations and changes to vaccination receipt.

There are several limitations to consider. Many ($N = 44$) of the identified studies reporting on vaccine uptake were surveys that relied on self-reported individuals’ vaccination history, which may have led to recall bias and a potential over- or underestimation of vaccine uptake. Despite potential biases in the estimated vaccine uptake, this literature review identified vaccine uptake data among several at-risk populations. Additionally, it should be noted that direct comparisons cannot be made between vaccine uptake rates due to the heterogeneity in sampling methods and study populations. Finally, the search was limited to the English Language; it may be possible that further evidence is published in other languages. However, this is a minor limitation, given the review was US-focused.

**Conclusions**

Despite the substantial burden that VPDs confer on both individuals and healthcare systems, vaccine uptake is suboptimal and remains below the Healthy People 2020 goals across many adult at-risk populations. This suboptimal vaccine uptake facilitates the continued burden of VPDs and therefore reinforces the importance of life-course immunization.

This literature review identified several key barriers to vaccination, including concerns regarding perceived vaccine safety and effectiveness, cost of vaccination, and lack of insurance and
provider recommendation. These barriers represent missed opportunities for vaccination of individuals in at-risk populations and emphasize the importance of continued education, clear guidelines, and policies to promote higher vaccine uptake. Embracing a national life-course immunization program provides opportunities to improve immunization policies and increases attention to the importance of vaccines throughout life.

Future research needs to focus on identifying the barriers to vaccination among these populations, in order to appropriately target individuals for vaccination and improve suboptimal vaccine uptake.

Disclosure statement

IK, MKN and MOB are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and may own stocks and/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. AK, DB, and IF are employees of Adelphi Values PROVE™. Adelphi Values PROVE™ was commissioned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA for the conduct of the study and development of the manuscript.

Funding

This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA. The funder contributed to the design of the study, collection, analysis, and interpretation of data as well as the writing and revision of the manuscript.

Author contributions

IK, MKN, MOB, AK, DB, and IF contributed to study conception and study design. All authors contributed to the writing of the manuscript. All authors reviewed and approved the final version of the manuscript.

References

1. World Health Organization. Immunization agenda 2030: a global strategy to leave no one behind. 2020.
2. Health Policy Partnership. A life-course approach to vaccination: adapting European policies. 2018.
3. Tate J, Aguado T, Bele JD, Holt D, Karafillakis E, Larson HJ, Nye S, Salisbury D, Votta M, Wait S, et al. The life-course approach to vaccination: harnessing the benefits of vaccination throughout life. Vaccine. 2019;37(44):6581–83. doi:10.1016/j.vaccine.2019.09.016.
4. Global Coalition on Aging. Life-course immunization: a driver of healthy aging. 2018.
5. Rémy V, Zollner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy. 2015;3. doi:10.3402/jmahp.v3i04.27041.
6. Centers for Disease Control and Prevention. Immunization schedules: recommended adult immunization schedule for ages 19 years or older, United States, 2021. Published 2021 [accessed 2022 Jan 28th]. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
7. Philip RK, Attwell K, Breuer T, Di Pasquale A, Lopalco PL. Life-Course immunization as a gateway to health. Expert Rev Vaccines. 2018;17(10):851–64. doi:10.1080/14760588.2018.1527690.
8. Zhang D, Petigara T, Yang X. Clinical and economic burden of pneumococcal disease in US adults aged 19-64 years with chronic or immunocompromising diseases: an observational database study. BMC Infect Dis. 2018;18(1):436. doi:10.1186/s12879-018-3326-z.
9. Caban-Martinez AJ, Lee DJ, Davila EP, LeBlanc WG, Arheart KL, McCollister KE, Christ SL, Clarke T, Fleming LE. Sustained low influenza vaccination rates in US healthcare workers. Prev Med. 2010;50(4):210–12. doi:10.1016/j.ympmed.2010.01.001.
10. Calabria CL, Vignari M, Yamshchikov A. Impact of patient safety and legislative standards on healthcare worker vaccination rates: a single center experience. Am J Infect Control. 2014;42(6 SUPPL. 1):S164. doi:10.1016/j.ajic.2014.03.348.
11. Control CID, Prevention. Influenza vaccination coverage among health-care personnel: 2011–12 influenza season, United States. MMWR Mortal Mortal Wkly Rep 2012;61:753.
12. Jegede O, Escamilla A, James F, Patton M, Kaye K, Chopra T. Implementing mandatory influenza vaccination policy for health care workers at a long term acute care facility. Am J Infect Control. 2012;40(5):e102–e103. doi:10.1016/j.ajic.2012.04.176.
13. Stark LM, Power ML, Turrentine M, Samelson R, Siddiqui MM, Paglia MJ, Strassberg ER, Kelly E, Murtough KL, Schulkin J, et al. Influenza vaccination among pregnant women: patient beliefs and medical provider practices. Infect Dis Obstet Gynecol. 2016;2016:3281975. doi:10.1155/2016/3281975.
14. Wagner S, Winston L, Chan SB. Health care workers and the mandated H1N1 vaccine: a survey to assess employee perception. Acad Emerg Med. 2011;18:S220–S221.
15. Black CL, Yue X, Ball SW, Donahue MA, Izrael D, de Perio MA, Laney AS, Williams WW, Lindley MC, Graitter SB, et al. Influenza vaccination coverage among health care personnel — United States, 2014–15 influenza season. Morb Mortal Wkly Rep. 2015;64(39):993–9. doi:10.15585/mmwr.mm6436a1.
16. Prevention CIDCa. Influenza vaccination coverage among health care personnel — United States, 2019–20 influenza season. 2020.
17. Lindley MC, Kahn KE, Bardenheier BH, D’Angelo DV, Dawood FS, Fink RV, Havers S, Skoff TH. Vital signs: burden and prevention of influenza and pertussis among pregnant women and infants — United States. Mortal Mortal Wkly Rep 2019;68(40):885. doi:10.15585/mmwr.mm6840e1.
18. Black CL, Xin Yue M, Ball SW, Fink R, de Perio MA, Laney AS, Williams WW, Lindley MC, Graitter SB, Lu P-J, et al. Influenza vaccination coverage among health care personnel — United States, 2016–17 influenza season. MMWR Morb Mortal Wkly Rep. 2017;66(38):1009. doi:10.15585/mmwr.mm6638a1.
19. Black CL, Yue X, Ball SW, Donahue MA, Izrael D, de Perio MA, Laney AS, Williams WW, Lindley MC, Graitter SB, et al. Influenza vaccination coverage among health care personnel — United States, 2015–16 influenza season. Morb Mortal Wkly Rep. 2016;65(38):1026–31. doi:10.15585/mmwr.mm6538a2.
20. Black CL, Yue X, Ball SW, et al. Influenza vaccination coverage among health care personnel—United States, 2013–14 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(37):805.
21. Zhang L, Wang Y, Peng M, She Q, Xiang Q, Chen Q, Liu Z, Zhang W, Tao N, Qiu L, et al. Prevalence and type distribution of high-risk human papillomavirus infections among women in Wufeng County, China. Arch Gynecol Obstet. 2012;286(3):695–99. doi:10.1007/s00404-012-2344-0.
22. Lindley MC, Zhang J, Euler GL. Health care personnel flu vaccination—Internet panel survey, United States, November 2011. Health Care (Don Mills). 2008;2007:2006–07.
23. Panda B, Stiller R, Panda A. Influenza vaccination during pregnancy and factors for lacking compliance with current CDC guidelines. J Maternal-Fetal Neonatal Med. 2011;24(3):402–06. doi:10.3109/14767058.2010.497882.
24. Centers for Disease Control and Prevention. Influenza vaccination coverage among Health care personnel — United States, 2018–19 influenza season. 2019. Centers for Disease Control and Prevention.
25. Centers for Disease Control and Prevention. Health care personnel and flu vaccination, Internet panel survey, United States, November 2017. 2018. Centers for Disease Control and Prevention.
26. Centers for Disease Control and Prevention. Health care personnel and flu vaccination, Internet panel survey, United States, November 2016. 2017. Centers for Disease Control and Prevention.
27. Centers for Disease Control and Prevention. Health care personnel and flu vaccination. Internet panel survey, United States, November 2015. 2016. Centers for Disease Control and Prevention.

28. Centers for Disease Control and Prevention. Health care personnel and flu vaccination. Internet panel survey, United States, November 2014. 2015. Centers for Disease Control and Prevention.

29. Centers for Disease Control and Prevention. Health care personnel and flu vaccination Internet panel survey, United States, November 2013. 2014. Centers for Disease Control and Prevention.

30. Centers for Disease Control and Prevention. Health Care Personnel Flu Vaccination Internet Panel Survey, United States, November 2012. 2013. Centers for Disease Control and Prevention.

31. Gornick W, Singh J, Santos N. Does tdap (Tetanus, diphtheria acellular pertussis) vaccine compliance increase with “mandatory” healthcare worker (HCW) influenza immunization (Flulmm) program? Am J Infect Control. 2010;38:E59–E60.

32. Gornick W, Santos N, Patel B, Singh J. Healthcare worker (HCW) pertussis (Tdap) vaccine compliance improves during a statewide pertussis epidemic. Am J Infect Control. 2012;40(5):e73. doi:10.1016/j.ajic.2012.04.130.

33. Collupudi LA, Jolly G, Kar K, Dhand A. Knowledge, attitude and practice survey regarding pertussis vaccination among transplant health care workers. Open Forum Infect Dis. 2017;4(Supplement 1):S517–S518. doi:10.1093/ofid/ofx136.1345.

34. Elsaid MI, Moyer RN, Narayan N, Li Y, John T, Rustgi VK. Hepatitis B vaccination coverage among native Hawaiian and pacific islanders: a population study of United States (US) adults. Hepatology. 2019;70(Suppl 1):583A–4A.

35. Guturu P, Cicalese L, Duchini A. Hepatitis a vaccination in health-care personnel. Ann Hepatol. 2012;11(3):326–29. doi:10.1016/S1665-2681(19)30927-5.

36. Yanni EA, Marano N, Han P, Edelson PJ, Blumensaadt S, Becker M, Dwyer S, Crocker K, Daley T, Davis X, et al. Knowledge, attitudes, and practices of US travelers to Asia regarding seasonal influenza and H5N1 avian influenza prevention measures. J Travel Med. 2010;17(6):374–81. doi:10.1111/j.1708-8305.2010.00458.x.

37. Hyle EP, Rao SR, Jentes ES, Parker Fiebelkorn A, Hagmann SHF, Taylor Walker A, Walensky RP, Ryan ET, LaRocque RC. Missed opportunities for measles, mumps, rubella vaccination among departing U.S. adult travelers receiving pretravel health consultations. Ann Intern Med. 2017;167(2):77–84. doi:10.7326/M16-2249.

38. Hyle EP, Fields NF, Fiebelkorn AP, Walker AT, Gastañaduy P, Rao SR, Ryan ET, LaRocque RC, Walensky RP. The clinical impact and cost-effectiveness of measles-mumps-Rubella vaccination to prevent measles importations among international travelers from the United States. Clin Infect Dis. 2019;69(2):306–15. doi:10.1093/cid/ciy611.

39. Williams WW, Lu P-J, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2014. Morb Mortal Wkly Rep. 2016;65(1):1–36.

40. Hochberg NS, Barnett ED, Chen LH, Wilson ME, Iyer H, MacLeod WB, Yanni E, Jentes ES, Karchmer AW, Ooi W, et al. International travel by persons with medical comorbidities: Understanding risks and providing advice. Mayo Clin Proc. 2013;88(11):1231–40.

41. Tian C, Ding X, Wang H, Wang W, Luo X. Characteristics associated with hepatitis B vaccination initiation and completion among adults traveling to a country of high or intermediate endemicity. Am J Infect Control. 2019;47(8):883–88. doi:10.1016/j.ajic.2019.02.014.

42. Lu P-J, Byrd KK, Murphy TV. Hepatitis a vaccination coverage among adults 18–49 years traveling to a country of high or intermediate endemicity, United States. Vaccine. 2013;31(19):2348–57. doi:10.1016/j.vaccine.2013.03.011.

43. Ha E, Kim F, Pan J, Hong DTP, Juon HS. Prevalence of viral hepatitis B and C infection among immigrants in the Baltimore-Washington metropolitan area screened from 2009-2014. Cancer Epidemiol Biomark Prev. 2016;25(Supplement 3):B37.

44. Mishra AC. Emerging viral infections in 21st century and their implications on health system. Indian J Virol. 2013;24:99–100.

45. Kilmer GA, Barkan W, Ly KN, Iles RB. Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015. Clin Infect Dis. 2019;68(2):256–65. doi:10.1093/cid/ciy749.

46. Levy V, Yuan J, Ruiz J, Morrow S, Reardon J, Facer M, Molfitor F, Allen B, Ajufo BG, Bell-Sanford G, et al. Hepatitis B sero-prevalence and risk behaviors among immigrant men in a population-based household survey in low-income neighborhoods of northern california. J Immigr Minor Health/center Minor Public Health. 2010;12(6):828–33. doi:10.1007/s10903-009-9239-6.

47. Ogunwobi OO, Dibba O, Zhu L, Ilboudo A, Tan Y, Fraser MA, Ma GX. Hepatitis B virus screening and vaccination in first-generation African immigrants: a pilot study. J Community Health. 2019;44(6):1037–43. doi:10.1007/s10900-019-00866-z.

48. Shaleh HM, Giama NH, Mohamed EA, et al. A cross-sectional assessment of knowledge, attitudes, and behaviors about viral hepatitis and hepatocellular carcinoma among Kenyan and Liberian immigrants living in Minnesota. Cancer Epidemiol Biomark Prev. 2016;25(Supplement 3):A46.

49. Xiong M, Nguyen RHN, Strayer L, Chandhanouvong S, Yuan J-M. Knowledge and behaviors toward hepatitis B and the hepatitis B vaccine in the Laotian community in Minnesota. J Immigr Minor Health. 2013;15(4):771–78. doi:10.1007/s10903-012-9768-2.

50. Bhattacharya M, Reiter PL, McRee AL. Nativity status and genital HPV infection among adults in the U.S. Hum Vaccin Immunother. 2019;15(7–8):1897–903. doi:10.1080/21645515.2019.1578592.

51. Dallo FJ, Kindratt TB. Disparities in vaccinations and cancer screening among U.S.- and foreign-born Arab and European American non-Hispanic White women. Women’s Health Issues. 2015;25(1):56–62. doi:10.1016/j.whi.2014.10.002.

52. Younossi ZM, Stepanova M. Changes in hepatitis a and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology (Baltimore, Md). 2011;54(4):1167–78. doi:10.1002/hep.24510.

53. Koenig A, Stepanova M, Felix S, Kalwaney S, Clement S, Younossi ZM. Vaccination against hepatitis a and B in patients with chronic liver disease and type 2 diabetes: has anything changed? Liver Int. 2016;36(8):1096–1100. doi:10.1111/liv.13164.

54. Annunziata K, Rak A, Del Buono H, DiBonaventura M, Krishnarajah G, Xu J. Vaccination rates among the general adult population and high-risk groups in the United States. PLoS ONE. 2012;7(11):e50553. doi:10.1371/journal.pone.050553.

55. Blumil BM, Watson LL, Skelton JB, Manolakis PG, Brock KA. Improving outcomes for diverse populations disproportionately affected by diabetes: final results of project IMPACT: diabetes. J Am Pharm Assoc. 2014;54(5):477–85. doi:10.1331/JPAA.2014.13240.

56. Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-Effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–21. doi:10.1016/j.vaccine.2013.10.024.

57. Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL, Cunningham AL. Vaccination of special populations: Protecting the vulnerable. Vaccine. 2016;34(52):6681–90. doi:10.1016/j.vaccine.2016.11.015.

58. Lu P, Santibanez TA, Williams WW, et al. Surveillance of influenza vaccination coverage–United States, 2007-08 through 2011-12 influenza seasons. Morb Mortal Wkly Rep Surveill Summ (Washington, DC). 2013;62(4):1–28.

59. O’Halloran AC, Lu P, Williams WW, Bridges CB, Singleton JA. Influence of influenza vaccine coverage among people with high-risk conditions in the U.S. Am J Prev Med. 2016;50(1):e15–e26. doi:10.1016/j.amepre.2015.06.008.
90. Cummings T, Kasting ML, Rosenberger JG, Rosenthal SL, Zimet GD, Stupiansky NW. Catching up or missing out? Human Papillomavirus vaccine acceptability among 18- to 26-year-old men who have sex with men in a US National Sample. Sex Transm Dis. 2015;42(11):601–6. doi:10.1097/OLQ.0000000000000358.

91. Reiter PL, Katz ML, Ruffin MT, Hade EM, DeGraffenreid CR, Patel DA, Paskett ED, Unger ER. HPV prevalence among women from Appalachia: results from the CARE project. PLoS ONE. 2013;8(8):e74276. doi:10.1371/journal.pone.0074276.

92. Goldstein ND, LeVasseur MT, Tran NK, Purtle J, Welles SL, Eppes SC. Modeling HPV vaccination scale-up among urban young men who have sex with men in the context of HIV. Vaccine. 2019;37(29):3883–91. doi:10.1016/j.vaccine.2019.05.047.

93. Gerend MA, Madkins K, Phillips G 2nd, Mustanski B. Predictors of human papillomavirus vaccination among young men who have sex with men. Sex Transm Dis. 2016;43(3):185–91. doi:10.1097/OLQ.0000000000000408.

94. Simon MS, Weiss D, Guevaruhes A, Krazt MM, Cutler B, Gulick RM, Zucker JR, Varma JK, Schackman BR. Cost-Effectiveness of meningococcal vaccination among men who have sex with men in New York City. J Acquir Immune Defic Syndr. 2016;71(2):146–54. doi:10.1097/QAI.0000000000000622.

95. Minard CG, Minard CM, Guffey D, Swaim LS, Opel DJ, Boom JA. Prevalence of vaccine hesitancy among expectant mothers in Houston, Texas. Acad Pediatr. 2018;18(2):154–60. doi:10.1016/j.acap.2017.08.003.

96. Ding H, Black CL, Ball S, Fink RV, Williams WW, Fiebelkorn AP, Lu P-J, Kahn KE, D’Angelo DV, Devlin R, et al. Influenza vaccination coverage among pregnant women — United States, 2016–17 influenza season. MMWR Morb Mortal Wkly Rep. 2017;66(38):1016–22. doi:10.15585/mmwr.mm6638a2.

97. Ding H. Pregnant Women and Flu Vaccination, Internet Panel Survey, United States, November 2016. CDC. 2016.

98. Ding H, Black CL, Ball S, Donahue S, Fink RV, Williams WW, Kennedy ED, Bridges CB, Lu P-J, Kahn KE, et al. Influenza Vaccination Coverage Among Pregnant Women — United States, 2014–15 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015;64(36):1000–05. doi:10.15585/mmwr.mm6436a2.

99. Chamberlain AT, Sicib K, Ault KA, Orenstein WA, Frew PM, Malik F, Cortés M, Costa P, Whitney EAS, Flowers LC, et al. Factors Associated with Intention to Receive Influenza and Tetanus, Diphtheria, and Acellular Pertussis vaccine (Tdap) Vaccines During Pregnancy: a Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety. PLoS Curr. 2015;7. doi:10.1371/currents.outbreaks.d37b61becebaeb5a7a06d4a0301ca819.

100. Scheminske M, Henninger M, Irving SA, Thompson M, Williams J, Shifflett P, Ball SW, Avalos LA, Naleway AL. The association between influenza vaccination and other preventative health behaviors in a cohort of pregnant women. Health Educ Behav. 2015;42(3):402–08. doi:10.1177/1090198114560021.

101. Ding H. Pregnant women and flu vaccination, Internet panel survey, United States, November 2013. CDC. 2013.

102. Drees M, Johnson O, Wong E, Stewart A, Fersini S, Silverman P, Ehrenthal D. Acceptance of 2009 H1N1 influenza vaccine among pregnant women in Delaware. Am J Perinatol. 2012;29(4):289–94. doi:10.1055/s-0031-1295660.

103. Memoli MJ, Harvey H, Morens DM, Taubenberger JK. Influenza in pregnancy. Influenza Other Respi Viruses. 2013;7(6):1033–39. doi:10.1111/irv.12053.

104. Fisher JS, Scott J, Hart J, Winn VD, Gibbs RS, Lynch AM. Behaviors and perceptions regarding seasonal and H1N1 influenza vaccination during pregnancy. Am J Obstet Gynecol. 2011;204(6 Suppl 1):S107–111. doi:10.1016/j.ajo.2011.02.041.

105. Centers for Disease C. Prevention. Influenza vaccination coverage among pregnant women—United States, 2012–13 influenza season. MMWR Mortal Mortal Wkly Rep. 2013;62(38):787–92.

106. Kerr S, Van Bennekum CM, Mitchell AA. Influenza vaccination coverage during pregnancy - selected sites, United States, 2005-06 through 2013-14 influenza vaccine seasons. MMWR Mortal Mortal Wkly Rep. 2016;65(48):1370–73. doi:10.15585/mmwr.mm6548a3.

107. Ding H, Kahn KE, Black CL, O’Halloran A, Lu P-J, Williams WW. Influenza vaccination coverage among pregnant women in the U.S., 2012–2015. Am J Prev Med. 2019;56(4):477–86. doi:10.1016/j.amepre.2018.11.020.

108. Groesch WC, Henninger ML, Smith N, et al. Influenza vaccination during pregnancy: influenza seasons 2002-2012, vaccine safety datalink. Am J Prev Med. 2016;50(4):88–90.

109. Drees M, Tambourelli B, Denstman A, Zhang W, Zent R, Mcgraw P, Ehrenthal DB. Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010–2011 influenza season. Vaccine. 2013;31(2):362–66. doi:10.1016/j.vaccine.2012.10.112.

110. Chamberlain AT, Berkelman RL, Ault KA, Rosenberg ES, Orenstein WA, Omer SB. Trends in reasons for non-receipt of influenza vaccination during pregnancy in Georgia, 2004–2011. Vaccine. 2016;34(13):1597–603. doi:10.1016/j.vaccine.2016.01.058.

111. Barber A, Muscoplat MH, Fedorowicz A. Coverage with Tetanus, Diphtheria, and Acellular Pertussis vaccine and influenza vaccine among pregnant women - Minnesota, March 2013-December 2014. MMWR Mortal Mortal Wkly Rep. 2017;66(2):56–59. doi:10.15585/mmwr.mm6602a4.

112. Beel ER, Rench MA, Montesinos DP, Mayes B, Healy CM. Knowledge and attitudes of postpartum women toward immunization during pregnancy and the peripartum period. Hum Vacc Immunother. 2013;9(9):1926–31. doi:10.4161/hvi.25096.

113. Butler AM, Laiyton JB, Li D, Hudgens MG, Boggess KA, McGrath LJ, Weber DJ, Becker-Drees S. Predictors of low uptake of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis immunization in privately insured women in the United States. Obstet Gynecol. 2017;129(4):629–37. doi:10.1097/AOG.0000000000001927.

114. Dempsey AF, Brewer SE, Sevick C, Pyrzawinski J, Mazzoni S, O’Leary ST. Tdap vaccine attitudes and utilization among pregnant women from a high-risk population. Hum Vacc Immunother. 2012(4):872–78. doi:10.1016/j.vaccine.2011.10.04594.

115. Kris J, Albert AP, Carter VM, Jiles AI, Liang JL, Mullen J, Rodriguez L, Howards PP, Orenstein WA, Omer SB, et al. Disparities in Tdap vaccination and vaccine information needs among pregnant women in the United States. Matern Child Health J. 2019;23(2):201–11. doi:10.1007/s10995-018-2633-8.

116. Payakachat N, Hadden KB, Ragland D. Promoting Tdap immunization in pregnancy: associations between maternal perceptions and vaccination rates. Vaccine. 2016;34(1):179–86. doi:10.1016/j.vaccine.2015.09.062.

117. Ahluwalia IB, Ding H, D’Angelo D, et al. Tetanus, diphtheria, pertussis vaccination coverage before, during, and after pregnancy - 16 States and New York City, 2011. States and New York City, 2011. MMWR Morb Mortal Wkly Rep. 2015;64(19):522–26.
